The Relative Strength (RS) Rating for McKesson (MCK) stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75.
↑ XThis exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 as they begin their biggest runs. See if McKesson stock can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
McKesson stock is trying to complete a cup without handle with a 637.51 buy point. See if it medical stock can break out in heavy trading.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 13%, compared to 8% in the prior report. Revenue increased from 6% to 21%.
McKesson stock holds the No. 3 rank among its peers in the Medical-Wholesale Drugs industry group. Cencora (COR) is the top-ranked stock within the group.
YOU MAY ALSO LIKE:
MarketSurge's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。